EP Patent

EP3698784A1 — Methods of treating lung cancer

Assigned to Abraxis Bioscience LLC · Expires 2020-08-26 · 6y expired

What this patent protects

The present invention provides compositions comprising nanoparticles that comprise paclitaxel and an albumin for use in a method of treating non-small-cell lung cancer (NSCLC), wherein the method comprises administering a) an effective amount of said composition and b) an effecti…

USPTO Abstract

The present invention provides compositions comprising nanoparticles that comprise paclitaxel and an albumin for use in a method of treating non-small-cell lung cancer (NSCLC), wherein the method comprises administering a) an effective amount of said composition and b) an effective amount of platinum-based agent (e.g., carboplatin), wherein the individual has four or more metastatic sites. Furthermore, said individual can be at least about 70 years old.

Drugs covered by this patent

Patent Metadata

Patent number
EP3698784A1
Jurisdiction
EP
Classification
—
Expires
2020-08-26
Drug substance claim
No
Drug product claim
No
Assignee
Abraxis Bioscience LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.